-
Je něco špatně v tomto záznamu ?
Possible effect of DHA intake on body weight reduction and lipid metabolism in obese children
L. Vasickova, P. Stavek, P. Suchanek,
Jazyk angličtina Země Švédsko
Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem
PubMed
22101886
Knihovny.cz E-zdroje
- MeSH
- antropometrie MeSH
- C-reaktivní protein analýza MeSH
- dítě MeSH
- hmotnostní úbytek účinky léků MeSH
- klinické křížové studie MeSH
- kyseliny dokosahexaenové farmakologie terapeutické užití MeSH
- kyseliny mastné omega-3 terapeutické užití MeSH
- lidé MeSH
- lipidy krev MeSH
- metabolismus lipidů účinky léků MeSH
- obezita dietoterapie farmakoterapie metabolismus MeSH
- tělesná hmotnost účinky léků fyziologie MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
OBJECTIVES: The aim of the study was to determine whether increased intake of DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid) would affect the weight loss or the various biochemical parameters in the blood of obese children following dietary/physical intervention. There were 120 obese (BMIs≥30 kg/m(2); mean 33.5 ± 3.9) children included in this randomized crossover study; aged 8-12 years (10.0 ± 1.9). METHODS: The children consumed an extra 300 mg DHA and 42 mg EPA (Haliborange ®) daily for a period of 3 weeks. Anthropometric and biochemical parameters were measured and documented for each of the subjects at the beginning of the study, after three weeks of treatment and at the end of the study. RESULTS: The daily consumption of 300 mg DHA and 42 mg of EPA was associated with decreased body weight (with DHA: 86.4 ± 19.6 to 80.8 ± 20.4 kg vs. without DHA: 85.6 ± 20.8 to 80.9 ± 19.9 kg; p<0.005) and total cholesterol concentration (with DHA: 3.72 ± 0.78 to 3.32 ± 0.53 mmol/l vs. without DHA: 3.74 ± 0.78 to 3.56 ± 0.56 mmol/l; p<0.05 and respectively with DHA). CONCLUSION: Daily consumption of 300 mg DHA and 42 mg EPA (Haliborange®) for 3 weeks leads to an improvement of the anthropometric and lipid parameters in obese children following dietary physical intervention.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12024252
- 003
- CZ-PrNML
- 005
- 20121210094827.0
- 007
- ta
- 008
- 120815s2011 sw f 000 0#eng||
- 009
- AR
- 035 __
- $a (PubMed)22101886
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sw
- 100 1_
- $a Vasickova, Ludmila $u Children's Institute Dr. L. Filip, Podebrady, Czech Republic.
- 245 10
- $a Possible effect of DHA intake on body weight reduction and lipid metabolism in obese children / $c L. Vasickova, P. Stavek, P. Suchanek,
- 520 9_
- $a OBJECTIVES: The aim of the study was to determine whether increased intake of DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid) would affect the weight loss or the various biochemical parameters in the blood of obese children following dietary/physical intervention. There were 120 obese (BMIs≥30 kg/m(2); mean 33.5 ± 3.9) children included in this randomized crossover study; aged 8-12 years (10.0 ± 1.9). METHODS: The children consumed an extra 300 mg DHA and 42 mg EPA (Haliborange ®) daily for a period of 3 weeks. Anthropometric and biochemical parameters were measured and documented for each of the subjects at the beginning of the study, after three weeks of treatment and at the end of the study. RESULTS: The daily consumption of 300 mg DHA and 42 mg of EPA was associated with decreased body weight (with DHA: 86.4 ± 19.6 to 80.8 ± 20.4 kg vs. without DHA: 85.6 ± 20.8 to 80.9 ± 19.9 kg; p<0.005) and total cholesterol concentration (with DHA: 3.72 ± 0.78 to 3.32 ± 0.53 mmol/l vs. without DHA: 3.74 ± 0.78 to 3.56 ± 0.56 mmol/l; p<0.05 and respectively with DHA). CONCLUSION: Daily consumption of 300 mg DHA and 42 mg EPA (Haliborange®) for 3 weeks leads to an improvement of the anthropometric and lipid parameters in obese children following dietary physical intervention.
- 650 _2
- $a antropometrie $7 D000886
- 650 _2
- $a tělesná hmotnost $x účinky léků $x fyziologie $7 D001835
- 650 _2
- $a C-reaktivní protein $x analýza $7 D002097
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a klinické křížové studie $7 D018592
- 650 _2
- $a kyseliny dokosahexaenové $x farmakologie $x terapeutické užití $7 D004281
- 650 _2
- $a kyseliny mastné omega-3 $x terapeutické užití $7 D015525
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a metabolismus lipidů $x účinky léků $7 D050356
- 650 _2
- $a lipidy $x krev $7 D008055
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a obezita $x dietoterapie $x farmakoterapie $x metabolismus $7 D009765
- 650 _2
- $a hmotnostní úbytek $x účinky léků $7 D015431
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Stavek, Petr
- 700 1_
- $a Suchanek, Pavel
- 773 0_
- $w MED00168352 $t Neuro endocrinology letters $x 0172-780X $g Roč. 32 Suppl 2(2011), s. 64-7
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22101886 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m
- 990 __
- $a 20120815 $b ABA008
- 991 __
- $a 20121210094904 $b ABA008
- 999 __
- $a ok $b bmc $g 946400 $s 781580
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2011 $b 32 Suppl 2 $d 64-7 $i 0172-780X $m Neuro-endocrinology letters $n Neuro-endocrinol. lett. $x MED00168352
- LZP __
- $a Pubmed-20120815/12/02